Arrowhead Pharmaceuticals, Inc.
Arrowhead Pharmaceuticals, Inc. Fundamental Analysis
Arrowhead Pharmaceuticals, Inc. (ARWR) shows moderate financial fundamentals with a PE ratio of 43.94, profit margin of 18.54%, and ROE of 36.12%. The company generates $1.1B in annual revenue with strong year-over-year growth of 232.58%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 81.9/100 based on profitability, valuation, growth, and balance sheet metrics. The B+ grade reflects solid fundamentals with room for improvement in valuation or growth.
Fundamental Health Score
We analyze ARWR's fundamental strength across five key dimensions:
Efficiency Score
ExcellentARWR demonstrates superior asset utilization.
Valuation Score
ModerateARWR shows balanced valuation metrics.
Growth Score
ExcellentARWR delivers strong and consistent growth momentum.
Financial Health Score
ExcellentARWR maintains a strong and stable balance sheet.
Profitability Score
ExcellentARWR achieves industry-leading margins.
Key Financial Metrics
Is ARWR Expensive or Cheap?
P/E Ratio
ARWR trades at 43.94 times earnings. This suggests a premium valuation.
PEG Ratio
When adjusting for growth, ARWR's PEG of 0.01 indicates potential undervaluation.
Price to Book
The market values Arrowhead Pharmaceuticals, Inc. at 15.63 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.
EV/EBITDA
Enterprise value stands at 23.70 times EBITDA. This signals the market has high growth expectations.
How Well Does ARWR Make Money?
Net Profit Margin
For every $100 in sales, Arrowhead Pharmaceuticals, Inc. keeps $18.54 as profit after all expenses.
Operating Margin
Core operations generate 27.55 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $36.12 in profit for every $100 of shareholder equity.
ROA
Arrowhead Pharmaceuticals, Inc. generates $12.61 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Arrowhead Pharmaceuticals, Inc. generates strong operating cash flow of $339.26M, reflecting robust business health.
Free Cash Flow
Arrowhead Pharmaceuticals, Inc. generates strong free cash flow of $321.97M, providing ample flexibility for dividends, buybacks, or growth.
FCF Per Share
Each share generates $2.30 in free cash annually.
FCF Yield
ARWR converts 3.60% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
43.94
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
0.01
vs 25 benchmark
P/B Ratio
Price to book value ratio
15.63
vs 25 benchmark
P/S Ratio
Price to sales ratio
8.14
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.55
vs 25 benchmark
Current Ratio
Current assets to current liabilities
3.38
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.36
vs 25 benchmark
ROA
Return on assets percentage
0.13
vs 25 benchmark
ROCE
Return on capital employed
0.24
vs 25 benchmark
How ARWR Stacks Against Its Sector Peers
| Metric | ARWR Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 43.94 | 29.43 | Worse (Expensive) |
| ROE | 36.12% | 800.00% | Weak |
| Net Margin | 18.54% | -20145.00% (disorted) | Strong |
| Debt/Equity | 0.55 | 0.30 | Weak (High Leverage) |
| Current Ratio | 3.38 | 4.64 | Strong Liquidity |
| ROA | 12.61% | -17936.00% (disorted) | Strong |
ARWR outperforms its industry in 3 out of 6 key metrics, particularly excelling in Net Margin, but lagging in P/E Ratio.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Arrowhead Pharmaceuticals, Inc.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
609.83%
Industry Style: Defensive, Growth, Innovation
High GrowthEPS CAGR
98.55%
Industry Style: Defensive, Growth, Innovation
High GrowthFCF CAGR
241.74%
Industry Style: Defensive, Growth, Innovation
High Growth